126 related articles for article (PubMed ID: 37598671)
1. Evaluation of Time to Onset and Outcome of Cardiac Adverse Events Associated with Nilotinib using Post-Marketing Surveillance.
Kanbayashi Y; Kojima A; Wakabayashi H; Shimizu T; Uchida M
Oncology; 2023; 101(12):799-807. PubMed ID: 37598671
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database.
Kanbayashi Y; Uchida M; Nakano K; Wakabayashi H; Shimizu T
Oncology; 2023; 101(6):397-405. PubMed ID: 37075717
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.
Kanbayashi Y; Tsuchiya E; Shimizu T; Uchida M
Daru; 2024 Jun; 32(1):279-287. PubMed ID: 38671257
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.
Kanbayashi Y; Shimizu T; Anzai M; Kawai R; Uchida M
Clin Drug Investig; 2023 Mar; 43(3):177-184. PubMed ID: 36780109
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao S; Uchida M; Satoki A; Okamoto K; Uesawa Y; Shimizu T
Oncology; 2022; 100(1):60-64. PubMed ID: 34673654
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Sci Rep; 2022 Sep; 12(1):15619. PubMed ID: 36114412
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Kanbayashi Y; Kobayashi M; Anzai M; Shimizu T; Uchida M
Oncology; 2023; 101(12):817-821. PubMed ID: 37591211
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.
Fujiwara M; Uchida M; Endo M; Goto M; Shimizu T
Oncology; 2023; 101(5):343-348. PubMed ID: 36889294
[TBL] [Abstract][Full Text] [Related]
12. Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization.
Khurana A; Arora MK; Dubey H
Daru; 2023 Dec; 31(2):107-118. PubMed ID: 37221442
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Cortes J; Mauro M; Steegmann JL; Saglio G; Malhotra R; Ukropec JA; Wallis NT
Am J Hematol; 2015 Apr; 90(4):E66-72. PubMed ID: 25580915
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Uchida M; Nakano K; Fujiwara M; Uesawa Y; Shimizu T
J Clin Pharm Ther; 2022 Aug; 47(8):1173-1180. PubMed ID: 35316861
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine.
Shabu A; Nishtala PS
Expert Rev Vaccines; 2023; 22(1):801-812. PubMed ID: 37723099
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.
Kawahara Y; Murata S; Shimizu T; Uesawa Y; Uchida M
In Vivo; 2023; 37(2):955-961. PubMed ID: 36881059
[TBL] [Abstract][Full Text] [Related]
17. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2022; 100(7):413-418. PubMed ID: 35504255
[TBL] [Abstract][Full Text] [Related]
19. Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.
McNeil MM; Cano M; R Miller E; Petersen BW; Engler RJ; Bryant-Genevier MG
Vaccine; 2014 Aug; 32(37):4758-65. PubMed ID: 24951868
[TBL] [Abstract][Full Text] [Related]
20. Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study.
Guan Y; Qi Y; Zheng L; Yang J; Zhang M; Zhang Q; Ji L
BMJ Open; 2023 Jan; 13(1):e068127. PubMed ID: 36669842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
